Michael Offin, MD
Internal Medicine · New York, NYNPI 1134564701
Payments from drug & device makers
What this record shows
This record is dominated by grants: $200,000 of the $223,995 with a category attached, or 89.3%. Genentech, Inc. accounts for 89.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $107,469, more than ten times the $7,576 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $10,182 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$200K
- Pfizer$9K
- Jazz Pharmaceuticals Inc.$4K
- Servier Bioinnovation$3K
- AstraZeneca$3K
- Novartis$3K
- plus $2K from 2 others
Across 90 payments — averaging $29,477 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Array Biopharma Inc$1.3M
- Gilead$616K
- Novartis$548K
- AstraZeneca$198K
- Pfizer$11K
What the payments were for
- Consulting fees$18,8908%
- Speaking & faculty fees$3,2001%
- Grants$200,00089%
- Travel & lodging$1,3431%
- Food & beverage$5610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $200,000 |
| Pfizer | 4 | $9,305 |
| Jazz Pharmaceuticals Inc. | 1 | $3,500 |
| Servier Bioinnovation | 1 | $3,400 |
| AstraZeneca | 11 | $2,891 |
| Novartis | 1 | $2,820 |
| Array Biopharma Inc | 1 | $2,000 |
| Astrazeneca UK Limited | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$223,995 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 82 | $1,333,399 |
| AlecensaAlectinib Hcl | 17 | $236,626 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $153,865 |
| XareltoRivaroxaban | 11 | $10,073 |
| Dexamethasone | 76 | $667 |
| Mirtazapine | 17 | $590 |
| Ondansetron Hcl | 40 | $400 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $361 |
| Oxycodone Hcl | 19 | $274 |
| Pantoprazole Sodium | 19 | $234 |
| Levothyroxine Sodium | 24 | $207 |
| Prednisone | 29 | $128 |
| Gabapentin | 16 | $81 |
| Folic Acid | 17 | $77 |
| Lorazepam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,891 | $1,333,39982 claims |
| NovartisMekinist | $2,820 | $153,86511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.